Xiaoyuan (Shawn) Chen
Publication Details
-
18F-labeled BBN-RGD heterodimer for prostate cancer imaging.
J Nucl Med. 2008; (3): 453-61
Both bombesin (BBN) analogs and cyclic RGD peptides have been suitably radiolabeled for prostate cancer imaging. However, the limited expression of gastrin-releasing peptide receptor (GRPR) and integrin alpha(v)beta(3) as well as unfavorable in vivo kinetics limited further applications of these imaging agents. We hypothesize that a peptide ligand recognizing both GRPR and integrin will be advantageous because of its dual-receptor-targeting ability.
Help